European Pharmaceutical Review

JUNE 27, 2023

Hervé Affagard (HA): Developing microbiome therapeutics as well as every other new therapeutic modality comes with several challenges that need to be addressed carefully to ensure patient safety and maximise the potential benefits of these treatments. Jeffrey Silber has been Chief Medical Officer of Vedanta Biosciences since 2020.

Food and Drug Administration 96

Food and Drug Administration Manufacturing Medicine Pharma 96

pharmaphorum

OCTOBER 26, 2022

There are many challenges in the development of therapies for rare diseases due to several unique factors, including small target patient populations, lack of long-term safety and efficacy data or natural history data, and often complex administration, dosing, and patient monitoring requirements,” Chiesi says. About the author.

Patients 78

Patients Pharma Consulting Transportation 78

PM360

AUGUST 9, 2022

According to an August 2021 report from the Business Research Company , after experiencing a decline in 2020 due to pandemic, the medication adherence market is expected to recover and grow at a compound annual growth rate (CAGR) of 11.4% KEEP was named in the top 100 best inventions list in TIME magazine following its launch in 2020.

Prescription 105

Prescription Medical Side effects Patients 105

Pharmaceutical Technology

FEBRUARY 26, 2023

This is largely due to the FDA’s rigorous approach to the safety of microbiome therapeutics, which has manifested in clinical holds, resulting in delays that have dimmed the enthusiasm in the space in recent times. While the French MaaT Pharma has submitted further information to the FDA, its trial remains on hold. with placebo.

Safety 111

Safety FDA Medicine Side effects 111

European Pharmaceutical Review

JANUARY 16, 2023

This also occupies a large resource, given the US Food and Drug Administration (FDA) requirement for double plate checking using a second ‘independent’ person. The FDA is doing this through the publications of Guidance for Industry. This places a continued reliance upon plate reading and the limitations of human vision.

Pharmaceutical 125

Pharmaceutical Food and Drug Administration Manufacturing FDA 125

Legacy MEDSearch

SEPTEMBER 1, 2022

eCential Robotics, a French growth MedTech company that designs and produces a system unifying 2D/3D imaging, surgical navigation and robotics, announced FDA 510(k) clearance of its 3D imaging, navigation and robotics guidance system, securing the penetration of its unified robotic platform in the United States. Securing the U.S.

FDA 52

FDA Recruitment Marketing Medical 52

PM360

SEPTEMBER 15, 2022

Cure” put me on a path to work across a network of incredibly smart, passionate, and well-meaning stakeholders to connect dots, create forums for sharing ideas, drive patient-centered approaches, and eliminate lost-in-translation moments. Fortunately, the industry is increasing its discussions around improving patient inclusion and DEI.

Patients 98

Patients Healthcare Healthcare Marketing 98

European Pharmaceutical Review

SEPTEMBER 22, 2023

Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.

Food and Drug Administration 75

Food and Drug Administration Safety Patients Leads 75

PM360

SEPTEMBER 7, 2023

Since 2020, diversity, equity, and inclusion (DE&I) has been a prime area of attention within healthcare and the life sciences. For one, the pandemic put a spotlight on the disparity within clinical trials—in 2020 the FDA found that 75% of trial participants were white, 11% were Hispanic, 8% were Black, and 6% were Asian.

Healthcare 111

Healthcare Healthcare Patients Education 111

Pharma Marketing Network

APRIL 30, 2021

The release in November of FDA’s final guidance on strategies to increase participation of underrepresented populations in trials ( “Enhancing the Diversity of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry” ) has given added impetus to these efforts.

Patients 52

Patients Pharma Recruitment Distribution 52

Cadensee

OCTOBER 19, 2021

Because we see these frequencies as kind of signatures, access codes to different networks that have been impaired in the brain as their own, as described before, and facilitating their recovery. In 2020 COVID came in and change the paradigm. So, the idea is that each network produces those kinds of ways when it operates.

Patients 52

Patients Medical Networking Marketing 52